NCT04797936View on ClinicalTrials.gov

BNO 1030 Extract (Imupret) in the Treatment of Mild Forms of COVID-19

PHASE4CompletedINTERVENTIONAL
Enrollment

133

Participants

Timeline

Start Date

May 1, 2020

Primary Completion Date

December 19, 2020

Study Completion Date

January 8, 2021

Conditions
Covid19NasopharyngitisAnosmiaFeverMyalgiaCoughNasal Congestion
Interventions
DRUG

BNO 1030

Imupret 25 drops х 6 times per day for 14 days

OTHER

Standard care

isolation mode symptomatic therapy as needed: antipyretic (paracetamol) saline solutions in the nose x 4 times a day -14 days

Trial Locations (1)

76000

Ivano-Frankivsk National Medical University, Ivano-Frankivsk

All Listed Sponsors
lead

Ivano-Frankivsk National Medical University

OTHER

NCT04797936 - BNO 1030 Extract (Imupret) in the Treatment of Mild Forms of COVID-19 | Biotech Hunter | Biotech Hunter